MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413893 | Name: DORA-22
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DORA-22 is an orexin receptor antagonist.

Chemical Structure

DORA-22
DORA-22
CAS#1088991-95-0

Theoretical Analysis

MedKoo Cat#: 413893

Name: DORA-22

CAS#: 1088991-95-0

Chemical Formula: C23H22F2N4O2

Exact Mass: 424.1711

Molecular Weight: 424.45

Elemental Analysis: C, 65.08; H, 5.22; F, 8.95; N, 13.20; O, 7.54

Price and Availability

Size Price Availability Quantity
1mg USD 350.00 2 Weeks
5mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
DORA-22; DORA 22; DORA22;
IUPAC/Chemical Name
Methanone, ((2R,5R)-5-(((5-fluoro-2-pyridinyl)oxy)methyl)-2-methyl-1-piperidinyl)(5-fluoro-2-(2-pyrimidinyl)phenyl)-
InChi Key
ADNQCBKNFSDDHY-HZPDHXFCSA-N
InChi Code
InChI=1S/C23H22F2N4O2/c1-15-3-4-16(14-31-21-8-6-18(25)12-28-21)13-29(15)23(30)20-11-17(24)5-7-19(20)22-26-9-2-10-27-22/h2,5-12,15-16H,3-4,13-14H2,1H3/t15-,16-/m1/s1
SMILES Code
O=C(N1[C@H](C)CC[C@@H](COC2=NC=C(F)C=C2)C1)C3=CC(F)=CC=C3C4=NC=CC=N4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 424.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gamble MC, Katsuki F, McCoy JG, Strecker RE, McKenna JT. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep. 2020 Mar 12;43(3):zsz241. doi: 10.1093/sleep/zsz241. PMID: 31595304. 2: Duncan MJ, Farlow H, Tirumalaraju C, Yun DH, Wang C, Howard JA, Sanden MN, O'Hara BF, McQuerry KJ, Bachstetter AD. Effects of the dual orexin receptor antagonist DORA-22 on sleep in 5XFAD mice. Alzheimers Dement (N Y). 2019 Feb 28;5:70-80. doi: 10.1016/j.trci.2019.01.003. PMID: 30859123; PMCID: PMC6396100. 3: Gamble MC, Katsuki F, McCoy JG, Strecker RE, McKenna JT. The Dual Orexin Receptor Antagonist DORA-22 Improves Mild Stress-induced Sleep Disruption During the Natural Sleep Phase of Nocturnal Rats. Neuroscience. 2021 Mar 15;463:30-44. doi: 10.1016/j.neuroscience.2021.03.003. Epub ahead of print. PMID: 33737028. 4: Yao L, Ramirez AD, Roecker AJ, Fox SV, Uslaner JM, Smith SM, Hodgson R, Coleman PJ, Renger JJ, Winrow CJ, Gotter AL. The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine. J Neurochem. 2017 Jul;142(2):204-214. doi: 10.1111/jnc.14055. Epub 2017 Jun 1. PMID: 28444767. 5: Iwakawa S, Kanmura Y, Kuwaki T. Orexin Receptor Blockade-Induced Sleep Preserves the Ability to Wake in the Presence of Threat in Mice. Front Behav Neurosci. 2019 Jan 8;12:327. doi: 10.3389/fnbeh.2018.00327. PMID: 30687033; PMCID: PMC6338018. 6: Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JI, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowlby MR, Kuduk SD, Coleman PJ, Hargreaves R, Winrow CJ, Renger JJ. Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology. 2013 Nov;38(12):2401-8. doi: 10.1038/npp.2013.139. Epub 2013 May 31. PMID: 23722242; PMCID: PMC3799059. 7: McDonald T, Liang HA, Sanoja R, Gotter AL, Kuduk SD, Coleman PJ, Smith KM, Winrow CJ, Renger JJ. Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain. J Neurogenet. 2016 Mar;30(1):32-41. doi: 10.3109/01677063.2016.1171862. PMID: 27276194. 8: Crow JM. Insomnia: chasing the dream. Nature. 2013 May 23;497(7450):S16-8. doi: 10.1038/497S16a. PMID: 23698503. 9: Tannenbaum PL, Tye SJ, Stevens J, Gotter AL, Fox SV, Savitz AT, Coleman PJ, Uslaner JM, Kuduk SD, Hargreaves R, Winrow CJ, Renger JJ. Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys. Sleep. 2016 Mar 1;39(3):603-12. doi: 10.5665/sleep.5536. PMID: 26943466; PMCID: PMC4763356. 10: Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC Neurosci. 2014 Sep 22;15:109. doi: 10.1186/1471-2202-15-109. PMID: 25242351; PMCID: PMC4261741.